Britain Approves GW Pharma’s Cannabis Drug Sativex
GW Pharmaceuticals Plc's cannabis-derived medicine Sativex has been approved in Britain for treating spasticity in patients with multiple sclerosis, in a landmark decision for the small drugmaker.
